GSK and Genmab file Arzerra for first-line use in US PMLiVE ... not responded to Genzyme's Campath (alemtuzumab) or the chemotherapy fludarabine, but has brought in relatively modest sales in that setting thanks to robust competition from Roche's Rituxan/ MabThera (rituximab), which has the same molecular target. |
